Related Experiment Video

Updated: Jan 21, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

355

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges

Orgilmaa Regzedmaa1, Hongbing Zhang1, Hongyu Liu2

  • 1Department of Lung Cancer Surgery, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, People's Republic of China.

Oncotargets and Therapy
|July 30, 2019
PubMed

Insights

Small cell lung cancer (SCLC) is aggressive but initially responds to chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1, offers new hope for treating SCLC patients.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Lung cancer is the leading cause of cancer death globally.
  • Small cell lung cancer (SCLC) is aggressive, with high initial chemotherapy response rates but rapid recurrence.
  • Recent advancements in cancer immunotherapy have shown significant promise.

Purpose of the Study:

  • To review the role of immunotherapy in treating small cell lung cancer (SCLC).
  • To discuss novel immune checkpoint inhibitors and combination strategies for SCLC.
  • To explore future opportunities and challenges in SCLC immunotherapy.

Main Methods:

  • Review of current literature on cancer immunotherapy and SCLC.
  • Discussion of immune checkpoint blockade mechanisms (CTLA-4, PD-1/PD-L1).
  • Analysis of rational combination strategies for SCLC treatment.

Main Results:

  • Immune checkpoint inhibitors (ICIs) demonstrate potential as SCLC therapeutics.
  • Blockade of CTLA-4 and PD-1/PD-L1 pathways are key strategies in immunotherapy.
  • Combination strategies are being explored to enhance therapeutic outcomes.

Conclusions:

  • Immunotherapy, especially ICIs, represents a promising avenue for SCLC treatment.
  • Further research into novel pathways and combination therapies is crucial for improving SCLC patient prognosis.
  • The future of SCLC treatment likely involves a combination of immunotherapy and other therapeutic modalities.
Keywords:
CTLA4PD1PDL1cytotoxic T lymphocyte-associated protein4immune checkpoint inhibitorsnext generation of immune checkpointsprogrammed cell death ligand 1programmed cell death protein1small cell lung cancer

More Related Videos

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung09:57

Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung

Published on: November 16, 2021

7.7K

Related Concept Videos

The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
What is the Immune System?01:38

What is the Immune System?

Overview
127.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.1K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
83.6K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.5K